Cargando…

Type IV collagen-derived angiogenesis inhibitor: canstatin low expressing in brain-invasive meningiomas using liquid chromatography–mass spectrometry (LC-MS/MS)

PURPOSE: Brain invasion in meningiomas is considered an indicator of more aggressive behavior and worse prognosis. But the precise definition and the prognostic role of brain invasion remains unsolved duo to lacking a standardized workflow of surgical sampling and the histopathological detection. Se...

Descripción completa

Detalles Bibliográficos
Autores principales: Pei, Jian, Li, Pei, Gao, Yun H., Tian, Bao G., Wang, Da Y., Zheng, Yu, Liu, Li Y., Zhang, Zhi Y., Huang, Si S., Wen, Min, Xu, Xiang, Xia, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9988792/
https://www.ncbi.nlm.nih.gov/pubmed/36811765
http://dx.doi.org/10.1007/s11060-023-04256-z
_version_ 1784901642173284352
author Pei, Jian
Li, Pei
Gao, Yun H.
Tian, Bao G.
Wang, Da Y.
Zheng, Yu
Liu, Li Y.
Zhang, Zhi Y.
Huang, Si S.
Wen, Min
Xu, Xiang
Xia, Lei
author_facet Pei, Jian
Li, Pei
Gao, Yun H.
Tian, Bao G.
Wang, Da Y.
Zheng, Yu
Liu, Li Y.
Zhang, Zhi Y.
Huang, Si S.
Wen, Min
Xu, Xiang
Xia, Lei
author_sort Pei, Jian
collection PubMed
description PURPOSE: Brain invasion in meningiomas is considered an indicator of more aggressive behavior and worse prognosis. But the precise definition and the prognostic role of brain invasion remains unsolved duo to lacking a standardized workflow of surgical sampling and the histopathological detection. Searching for molecular biomarker expression correlating with brain invasion, could contribute to establish a molecular pathological diagnosis without problems of subjective interobserver variation and deeply understand the mechanism of brain invasion and develop innovative therapeutic strategies. METHODS: We utilized liquid chromatography tandem mass spectrometry to quantify protein abundances between non-invasive meningiomas (n = 21) and brain-invasive meningiomas (n = 21) spanning World Health Organization grades I and III. After proteomic discrepancies were analyzed, the 14 most up-regulated or down-regulated proteins were recorded. Immunohistochemical staining for glial fibrillary acidic protein and most likely brain invasion-related proteins was performed in both groups. RESULTS: A total of 6498 unique proteins were identified in non-invasive and brain-invasive meningiomas. Canstatin expression in the non-invasive group was 2.1-fold that of the brain-invasive group. The immunohistochemical staining showed canstatin expressed in both groups, and the non-invasive group showed stronger staining for canstatin in the tumor mass (p = 0.0132) than the brain-invasive group, which showed moderate intensity. CONCLUSION: This study demonstrated the low expression of canstatin in meningiomas with brain invasion, a finding that provide a basis for understanding the mechanism of brain invasion of meningiomas and may contribute to establish molecular pathological diagnosis and identify novel therapeutic targets for personalized care. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11060-023-04256-z.
format Online
Article
Text
id pubmed-9988792
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-99887922023-03-08 Type IV collagen-derived angiogenesis inhibitor: canstatin low expressing in brain-invasive meningiomas using liquid chromatography–mass spectrometry (LC-MS/MS) Pei, Jian Li, Pei Gao, Yun H. Tian, Bao G. Wang, Da Y. Zheng, Yu Liu, Li Y. Zhang, Zhi Y. Huang, Si S. Wen, Min Xu, Xiang Xia, Lei J Neurooncol Research PURPOSE: Brain invasion in meningiomas is considered an indicator of more aggressive behavior and worse prognosis. But the precise definition and the prognostic role of brain invasion remains unsolved duo to lacking a standardized workflow of surgical sampling and the histopathological detection. Searching for molecular biomarker expression correlating with brain invasion, could contribute to establish a molecular pathological diagnosis without problems of subjective interobserver variation and deeply understand the mechanism of brain invasion and develop innovative therapeutic strategies. METHODS: We utilized liquid chromatography tandem mass spectrometry to quantify protein abundances between non-invasive meningiomas (n = 21) and brain-invasive meningiomas (n = 21) spanning World Health Organization grades I and III. After proteomic discrepancies were analyzed, the 14 most up-regulated or down-regulated proteins were recorded. Immunohistochemical staining for glial fibrillary acidic protein and most likely brain invasion-related proteins was performed in both groups. RESULTS: A total of 6498 unique proteins were identified in non-invasive and brain-invasive meningiomas. Canstatin expression in the non-invasive group was 2.1-fold that of the brain-invasive group. The immunohistochemical staining showed canstatin expressed in both groups, and the non-invasive group showed stronger staining for canstatin in the tumor mass (p = 0.0132) than the brain-invasive group, which showed moderate intensity. CONCLUSION: This study demonstrated the low expression of canstatin in meningiomas with brain invasion, a finding that provide a basis for understanding the mechanism of brain invasion of meningiomas and may contribute to establish molecular pathological diagnosis and identify novel therapeutic targets for personalized care. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11060-023-04256-z. Springer US 2023-02-22 2023 /pmc/articles/PMC9988792/ /pubmed/36811765 http://dx.doi.org/10.1007/s11060-023-04256-z Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research
Pei, Jian
Li, Pei
Gao, Yun H.
Tian, Bao G.
Wang, Da Y.
Zheng, Yu
Liu, Li Y.
Zhang, Zhi Y.
Huang, Si S.
Wen, Min
Xu, Xiang
Xia, Lei
Type IV collagen-derived angiogenesis inhibitor: canstatin low expressing in brain-invasive meningiomas using liquid chromatography–mass spectrometry (LC-MS/MS)
title Type IV collagen-derived angiogenesis inhibitor: canstatin low expressing in brain-invasive meningiomas using liquid chromatography–mass spectrometry (LC-MS/MS)
title_full Type IV collagen-derived angiogenesis inhibitor: canstatin low expressing in brain-invasive meningiomas using liquid chromatography–mass spectrometry (LC-MS/MS)
title_fullStr Type IV collagen-derived angiogenesis inhibitor: canstatin low expressing in brain-invasive meningiomas using liquid chromatography–mass spectrometry (LC-MS/MS)
title_full_unstemmed Type IV collagen-derived angiogenesis inhibitor: canstatin low expressing in brain-invasive meningiomas using liquid chromatography–mass spectrometry (LC-MS/MS)
title_short Type IV collagen-derived angiogenesis inhibitor: canstatin low expressing in brain-invasive meningiomas using liquid chromatography–mass spectrometry (LC-MS/MS)
title_sort type iv collagen-derived angiogenesis inhibitor: canstatin low expressing in brain-invasive meningiomas using liquid chromatography–mass spectrometry (lc-ms/ms)
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9988792/
https://www.ncbi.nlm.nih.gov/pubmed/36811765
http://dx.doi.org/10.1007/s11060-023-04256-z
work_keys_str_mv AT peijian typeivcollagenderivedangiogenesisinhibitorcanstatinlowexpressinginbraininvasivemeningiomasusingliquidchromatographymassspectrometrylcmsms
AT lipei typeivcollagenderivedangiogenesisinhibitorcanstatinlowexpressinginbraininvasivemeningiomasusingliquidchromatographymassspectrometrylcmsms
AT gaoyunh typeivcollagenderivedangiogenesisinhibitorcanstatinlowexpressinginbraininvasivemeningiomasusingliquidchromatographymassspectrometrylcmsms
AT tianbaog typeivcollagenderivedangiogenesisinhibitorcanstatinlowexpressinginbraininvasivemeningiomasusingliquidchromatographymassspectrometrylcmsms
AT wangday typeivcollagenderivedangiogenesisinhibitorcanstatinlowexpressinginbraininvasivemeningiomasusingliquidchromatographymassspectrometrylcmsms
AT zhengyu typeivcollagenderivedangiogenesisinhibitorcanstatinlowexpressinginbraininvasivemeningiomasusingliquidchromatographymassspectrometrylcmsms
AT liuliy typeivcollagenderivedangiogenesisinhibitorcanstatinlowexpressinginbraininvasivemeningiomasusingliquidchromatographymassspectrometrylcmsms
AT zhangzhiy typeivcollagenderivedangiogenesisinhibitorcanstatinlowexpressinginbraininvasivemeningiomasusingliquidchromatographymassspectrometrylcmsms
AT huangsis typeivcollagenderivedangiogenesisinhibitorcanstatinlowexpressinginbraininvasivemeningiomasusingliquidchromatographymassspectrometrylcmsms
AT wenmin typeivcollagenderivedangiogenesisinhibitorcanstatinlowexpressinginbraininvasivemeningiomasusingliquidchromatographymassspectrometrylcmsms
AT xuxiang typeivcollagenderivedangiogenesisinhibitorcanstatinlowexpressinginbraininvasivemeningiomasusingliquidchromatographymassspectrometrylcmsms
AT xialei typeivcollagenderivedangiogenesisinhibitorcanstatinlowexpressinginbraininvasivemeningiomasusingliquidchromatographymassspectrometrylcmsms